<DOC>
	<DOCNO>NCT01907802</DOCNO>
	<brief_summary>This phase I trial study side effect best dose dabrafenib treat patient solid tumor kidney liver dysfunction . Dabrafenib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Dabrafenib Treating Patients With Solid Tumors Kidney Liver Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine toxicity profile maximum tolerate dos ( MTDs ) dabrafenib patient v-raf murine sarcoma viral oncogene homolog B1 ( BRAF ) ^V600X mutation renal hepatic dysfunction . SECONDARY OBJECTIVES : I . To assess tumor response various time clinical event . II . To provide dose recommendation dabrafenib patient vary degree hepatic renal dysfunction possible inclusion label . TERTIARY OBJECTIVES : I . To assess pharmacokinetic pharmacogenetic profile dabrafenib active metabolite . OUTLINE : This dose-escalation study . Patients receive dabrafenib orally ( PO ) twice daily ( BID ) day 1-28 ( daily [ QD ] day 1 course 1 ) . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>PREREGISTRATION ELIGIBILITY CRITERIA Willing provide tissue require per protocol central BRAF^V600X mutation test NOTE : patient prior BRAF^600X test demonstrate mutation V600X allow enroll prior central test assay perform Clinical Laboratory Improvement Amendments ( CLIA ) certify laboratory assay ; include THxID , BRAF Detection Kit , Cobas 4800 BRAF600 mutation test CLIAcertified assay available participate institution Patients unknown BRAF^600X status : histologically confirm melanoma , papillary thyroid , cholangiocarcinoma testicular cancer metastatic unresectable investigator feel BRAF^600X target agent reasonable treatment NOTE : patient must screen central BRAF testing must demonstrate V600 mutation prior start study agent Note : tumor type without know BRAF^600X mutation eligible central test Ability understand willingness sign write informed consent Life expectancy &gt; 3 month REGISTRATION ELIGIBILITY CRITERIA Patients know BRAF^V600X mutation : patient must BRAF^V600X mutate , histologically confirm cancer metastatic unresectable curative standard therapy exist longer effective NOTE : colorectal cancer BRAF mutation ARE NOT allow NOTE : mutation V600 position result change V ( valine ) allow ; include E , D , K , R mutation note V600 position Any number follow prior therapy allow : Chemotherapy &gt; = 28 day prior registration Mitomycin C/nitrosoureas &gt; = 42 day prior registration Immunotherapy &gt; = 28 day prior registration Biologic therapy &gt; = 28 day prior registration Radiation therapy &gt; = 28 day prior registration Radiation &lt; 25 % bone marrow Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( Karnofsky &gt; = 70 % ) Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Absolute neutrophil count ( ANC ) &gt; = 1.2 x 10^9/L Hemoglobin &gt; = 9 g/dL Platelets &gt; = 100 x 10^9/L Albumin &gt; = 2.5 g/dL NOTE : applies patient normal renal dysfunction cohort ( N , R3 R4 ) ; abnormal albumin allow patient liver dysfunction cohort Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x institutional upper limit normal ( ULN ) NOTE : applies patient normal renal dysfunction cohort ( N , R3 R4 ) ; patient elevate AST and/or ALT may assign liver dysfunction cohort Prothrombin time ( PT ) /international normalize ratio ( INR ) partial thromboplastin time ( PTT ) = &lt; 1.3 x institutional ULN ; subject receive anticoagulation treatment may allow participate INR establish within therapeutic range prior randomization NOTE : applies patient normal renal dysfunction cohort ( N , R3 R4 ) ; elevate PT/INR allow patient liver dysfunction cohort Left ventricular ejection fraction &gt; = institutional low limit normal ( LLN ) echocardiogram ( ECHO ) Hepatic renal function meeting stratum : Group N : Hepatic : normal function ( bilirubin = &lt; ULN ; AST = &lt; ULN ) ; renal : normal function ( creatinine clearance [ CrCl ] &gt; = 60 mL/min estimate Cockcroft Gault equation ) Group R3 : Hepatic : normal function ( bilirubin = &lt; ULN ; AST = &lt; ULN ) ; renal : severe dysfunction ( CrCl &gt; = 15 &lt; 30 mL/min estimate Cockcroft Gault equation ) Group R4 : Hepatic : normal function ( bilirubin = &lt; ULN ; AST = &lt; ULN ; renal : renal failure ( hemodialysis ) Group H1 : Hepatic : mild dysfunction ( bilirubin = &lt; ULN ; AST &gt; ULN ) ; renal : acceptable function ( CrCl &gt; = 60 mL/min estimate Cockcroft Gault equation ) Group H2 : Hepatic : moderate dysfunction ( bilirubin &gt; ULN = &lt; 3 x ULN ; AST &gt; ULN ) ; renal : acceptable function ( CrCl &gt; =â‰¥ 60 mL/min estimate Cockcroft Gault equation ) Group H3 : Hepatic : severe dysfunction ( bilirubin &gt; 3 x ULN investigator discretion ; AST &gt; ULN ) ; renal : acceptable function ( CrCl &gt; = 60 mL/min estimate Cockcroft Gault equation ) Women childbearing potential must negative serum pregnancy test = &lt; 7 day prior registration Women childbearing potential men must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 1 month completion dabrafenib administration Ability understand willingness sign write informed consent document Willingness provide blood tissue sample require per protocol Patients history clinical benefit prior RAF inhibitor therapy , judge investigator , allow Patients active biliary obstruction ; NOTE : patient shunt place least 10 day prior first dose dabrafenib allow Reduced leave ventricular ejection fraction ( &lt; 50 % ) evidence cardiac dysfunction determine investigator Use investigational anticancer drug within 28 day precede first dose dabrafenib Patients receive medication substance strong inhibitor inducer cytochrome P450 , family 3 , subfamily A ( CYP3A ) cytochrome P450 family 2 , subfamily C , polypeptide 8 ( CYP2C8 ) ineligible For patient intermediate inducer inhibitor , attempt make switch alternative agent delay enrollment treatment course concomitant agent complete ; possible , patient may enrol felt patient best interest decide investigator Weak inhibitor CYP3A CYP2C8 use caution attempt make limit use find alternative agent , possible Warfarin use provisionally allow Unresolved toxicity National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI CTCAE v4.0 ) grade 2 high previous anticancer therapy , except alopecia Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible ; Note : patient antiretroviral therapy eligible study Uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes mellitus , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Presence malignancy study indication trial within 5 year study enrollment History evidence cardiovascular risk include follow : QT interval correct heart rate use Bazett 's formula QTcB &gt; = 480 msec History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within past 24 week prior randomization History evidence current class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system Intracardiac defibrillator Abnormal cardiac valve morphology ( &gt; = grade 2 ) document ECHO ; ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) ; subject moderate valvular thickening enter study History evidence current clinically significant uncontrolled cardiac arrhythmia ; clarification : subject atrial fibrillation control &gt; 30 day prior dose eligible Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control anti hypertensive therapy Brain metastases symptomatic untreated stable &gt; = 3 month ( must document imaging ) require corticosteroid ; subject stable dose corticosteroid &gt; 1 month corticosteroid least 2 week enrol approval Cancer Therapy Evaluation Program ( CTEP ) medical monitor ; subject must also enzymeinducing anticonvulsant &gt; 4 week History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week ; class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system ; history know cardiac arrhythmia unless stably control History allergic reaction attribute compound similar chemical biologic composition dabrafenib agent use study Pregnant woman exclude study ; breastfeed discontinue mother treated dabrafenib Any condition medical problem addition underlie malignancy organ dysfunction investigator feel would pose unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>